Invesco S&P 500 Momentum ETF vs Twist Bioscience Corp — how do they compare? Invesco S&P 500 Momentum ETF trades at $149.66, while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). Which is the better fit depends on your goals.
| SPMO | TWST | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $102.88 |
52-Week Low | $107.84 | $24.16 |
Market Cap | — | $5.45B |
Enterprise Value | — | $5.37B |
Signals from Pluang's Aura AI — not financial advice
SPMO trades at $144.50 with a slight 0.42% daily gain. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights strong momentum performance, with the ETF gaining 7.5% in June 2026 and leading S&P factors. The portfolio is concentrated in technology stocks, benefiting from AI-driven growth but facing volatility risks.
Outlook remains mixed; AI momentum supports growth, but high concentration and bearish technicals pose risks. Investors should weigh the ETF's rules-based strategy against potential sector rotations. Dividend of $0.25 is scheduled for June 2026, adding income appeal amid market uncertainty.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →